Orbit Genomics
Orbit Genomics, Inc.
Orbit Genomics, Inc. is a biotechnology company developing an AI-driven genomics platform focused on precision medicine. By analyzing a novel area of the genome known as short tandem repeats (STRs), the company aims to provide a more comprehensive understanding of both inherited and acquired risk for complex diseases like cancer and heart disease. Their technology is designed to create clinically actionable, non-invasive tests to improve diagnosis and treatment.
Products & Team
OrbiSeq™ Platform
The OrbiSeq™ Platform is the company's core, AI-powered technology that analyzes short tandem repeats (STRs) from a simple blood draw. It uses proprietary algorithms to process genomic data that is often considered 'noise' by standard technologies, making it applicable for developing tests for a wide range of complex diseases.
It solves the challenge of accurately diagnosing and assessing risk for complex diseases by analyzing a more dynamic part of the genome, providing clinicians with actionable insights that can reduce the need for invasive procedures and enable personalized treatment plans.
For clinicians and patients, the primary pain point is the uncertainty and high cost associated with indeterminate findings from CT scans, which often leads to stressful, expensive, and potentially risky invasive biopsies. For pharmaceutical partners, the challenge is identifying the right patient population for a specific therapy to improve clinical trial success and treatment efficacy.